Orpheris' technology platform consists of hydroxyl dendrimers that specifically target reactive microglia and reactive astrocytes associated with neuroinflammation resulting in demyelination and neuronal loss.

How Our Technology Works:


Broad Applications of the Platform Technology:

Selective targeting to activated cells

Enables drugs to cross the BBB and penetrate into regions of inflammation and tumors

No off-target toxicity

Specific targeting to activated
microglia and macrophage

Tunable functionality with multiple
linkers and chemistries

Diverse payloads and ability to
quickly screen drug candidates

Flexible route of
administration: Oral, SC, IV

Optimal product profile